Wednesday, June 10, 2026
🇺🇸 FDA

Drug profile · INN

powder

powder is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 20
Pipeline programs 364
News articles 0
Drug details — powder
Class
—
Route
—
Patents
20
Programs
364
Data quality
0.70
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

powder is an FDA-listed pharmaceutical active ingredient.

Key facts

INN powder

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Search pipeline
  1. 042011 Phase 3 · George Institute for · Langerhans Cell Histiocytosis
  2. 071102 Phase 3 · Baxalta Innovations · Hereditary severe von Willebrand Disease in children
  3. 111-302 Phase 3 · BioMarin Pharmaceutical Australia · Achondroplasia
  4. 111-303 Phase 3 · BioMarin Pharmaceutical Australia · Hypochondroplasia
  5. 111-308 Phase 3 · BioMarin Pharmaceutical Australia · Hypochondroplasia
  6. 1479-0008 Phase 3 · Boehringer Ingelheim · non-squamous non-small cell lung cancer
  7. 20170770 Phase 3 · Amgen · Chemotherapy-induced Thrombocytopenia in Adult subjects with
  8. 2019/2894 Phase 3 · George Institute for · Patients with High Risk Neuroblastoma

Related patents

Browse patents

  1. US 12370241

    Nasal powder formulation for treatment of hypoglycemia

    Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12280088

    Dry powder formulation of caveolin-1 peptides and methods of use thereof

    Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12280089

    Dry powder formulation of caveolin-1 peptides and methods of use thereof

    Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12226456

    Nasal powder formulation for treatment of hypoglycemia

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11802237

    Method for producing powder containing zirconia particles and fluorescent agent

    Expires Mon Oct 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10960044

    Powder formulation having hypoglycemic and hypolipidemic functions and method for preparing the same

    Expires Mon Mar 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10835514

    Dry powder inhaler compositions of 7-azoniabicyclo[2.2.1]heptane derivatives

    Expires Mon Nov 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10820615

    Powder formulation having a function of enhancing immunity and method for preparing the same

    Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10821146

    Powder formulation having a function of enhancing immunity and method for preparing the same

    Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10813961

    Powder formulation having a function of enhancing immunity and method for preparing the same

    Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10507225

    Powder for regulating intestinal flora and protecting gastric mucosa, preparation method and use thereof

    Expires Mon Dec 12 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10415881

    Method and device for freeze-drying drug liposomes powder assisted by variable-frequency alternating-current electric field

    Expires Mon Sep 12 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10406194

    Powder formulation, method for preparing the same and use thereof

    Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9980904

    Dry powder formulation

    Expires Mon May 24 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9724376

    Olive leaf powder

    Expires Mon Aug 03 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9603907

    Dry powder formulations of dNase I

    Expires Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9517210

    Method for producing microcapsule powder

    Expires Mon Dec 08 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9415008

    Dry powder inhaler

    Expires Mon Aug 11 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9226881

    Multi-functional composite powder

    Expires Mon Dec 31 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9066957

    Dry powder inhaler

    Expires Mon Jun 25 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is powder?

powder is an FDA-listed pharmaceutical active ingredient.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.